H. Lundbeck A/s

Glycom A/s

Nikolay Khanzhin

William Patrick Watson

Markus Jondelius Hederos

Karsten Juhl

Mario Rottlander

Pierre Chassagne

Andreas Ritzen

Mario Rottländer

Christian Wenzel Tornoe

Martin Matwiejuk

Daniel Rodriguez Greve

Klaus Baek Simonsen

Soren Moller Nielsen

Christian Wenzel Tornøe

Søren Møller Nielsen

Andreas Ritzèn

Jan Kehler

Bruce McConnell

Lars Kyhn Rasmussen

Louise Kristine Vigsnæs

Gyula Dekany

Elise Champion

Morten Bang Norgaard

Klaus Bæk Simonsen

Andreas Ritzén

Niels Banke

Agnese Maggi

Christian Wenzel Thornøe

The invention relates to a method for separating sialylated oligosaccharides, preferably sialylated human milk oligosaccharides (HMOs), from disaccharides, preferably lactose, produced by a fermentation or enzymatic process.

Purification of oligosaccharides

This invention relates to a method for the enzymatic synthesis of oligosaccharides, preferably human milk oligosaccharides (HMOs) The method comprises the enzymatic transfer of a glycosyl moiety and subsequent removal of by-products, such as lactose, by nanofiltration using a membrane comprising an active polyamide layer.

Synthesis of oligosaccharides

The present disclosure relates to synthetic mixtures of certain human milk oligosaccharides and uses thereof. Particular mixtures provided herein include: lacto-N-triose II, lacto-N-neotetraose, para-lacto-N-neohexaose, and, optionally, lactose; and lacto-N-triose II, lacto-N-tetraose, para-lacto-N-hexaose II, and, optionally, lactose. These mixtures are useful in the prevention and treatment of viral and bacterial infections.

Compositions comprising HMOS, their production and use for the prevention and/or treatment of viral and/or bacterial infections

The present invention relates to a method of removing residual organic solvent from crystalline oligosaccharides by the use of water vapour as well as the pharmaceutically and nutritionally suitable crystalline oligosaccharides obtained by said method.

Method for removing residual organic solvent from a crystalline oligosaccharide

The invention relates to a method for obtaining an N-acetylglucosamine containing neutral oligosaccharide from a fermentation broth, wherein said oligosaccharide is produced by culturing a genetically modified microorganism capable of producing said oligosaccharide from an internalized carbohydrate precursor, comprising the steps of: i) ultrafiltration (UF), preferably to separate biomass from the broth, ii) nanofiltration (NF), preferably to concentrate said oligosaccharide in the broth and/or reduce an inorganic salt content of the broth, and iii) treating the broth with an ion exchange resin, preferably to remove charged materials, and/or subjecting the broth to chromatography, preferably to remove hydrophobic impurities.

Separation of oligosaccharides from fermentation broth

The invention relates to separation of disaccharides from tri- or higher oligosaccharides by nanofiltration.

The present invention relates to a method for separating sialylated oligosaccharides from a fermentation broth in which they are produced by a genetically modified microorganism The separation comprises the steps of: i) ultrafiltration; ii) nano-filtration; iii) optionally, activated charcoal treatment; and iv) treatment with strong anion and/or cation exchange resin.

Crystalline pLNnH, useful in a pharmaceutical or nutritional composition, is disclosed.

Crystalline HMO

An achemo-enzymatic synthesis of oligosaccharides of formula 1 is presented wherein R is selected from &#x2014;OH, &#x2014;N 3 and &#x2014;OR 6 wherein R 6 is selected from allyl optionally substituted by one or more methyl, propargyl optionally substituted by one or more methyl, 2-trimethylsilyl-ethyl, &#x2014;(CH 2) n &#x2014;NH 2 and &#x2014;(CH 2) n &#x2014;N 3 wherein integer n is to 10, preferably 2 or 3, R is selected from sialyl moiety, &#x2014;SO 3 H and &#x2014;CH(R)&#x2014;COOH wherein R is selected from H, alkyl and benzyl, R 2 is selected from H and fucosyl, R 3 is selected from H and sialyl, R 4 is selected from H and fucosyl, provided that at least one of R 3 and R 4 is H, and A is a divalent carbohydrate linker, having important biological activities and significant commercial value for the pharmaceutical and food industry.

Synthesis of sialylated/fucosylated human milk oligosaccharides

Isoquinolone derivatives of the general formula Ik&#x2033; are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia. 

Isoquinolinone derivatives as NK3 antagonists

Isoquinolone derivatives of the general formula (I) are NK3 antagonists. 

Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia. 

The present invention relates to pyridine derivatives of the general formula (I) and their use as openers of the KCNQ family potassium ion channels for the treatment of CNS disorders. 

Substituted pyridine derivatives

The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

Growing community of inventors

Humlebaek, Denmark

Nikolay Khanzhin